ARALEZ PHARMACEUTICALS INC. (NASDAQ:ARLZ) Files An 8-K Entry into a Material Definitive Agreement

ARALEZ PHARMACEUTICALS INC. (NASDAQ:ARLZ) Files An 8-K Entry into a Material Definitive Agreement
Item 9.01. Entry into a Material Definitive Agreement.

Story continues below

In connection with its review of strategic alternatives, on June29, 2018, Aralez Pharmaceuticals Inc. (the “Company”) entered into an Amendment (the “Amendment”) to that certain Second Amended and Restated Facility Agreement, dated as of December7, 2015, as amended on October3, 2016 (the “Facility Agreement”), by and between the Company and Deerfield Partners, L.P. (“Deerfield”) and certain affiliates of each party.

to the terms of the Amendment, interest due and payable on July1, 2018 with respect to the loans under the Facility Agreement will be paid in kind, added to the outstanding principal amount of such loansand bear interest at the applicable interest rate of such loans. The amount of interest paid in kind and the interest thereon is due and payable without premium or penalty on August15, 2018 or such earlier date as loans maybe become due and payable.

The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by referenceto the full text of the Amendment. A copy of Amendment is included as Exhibit10.1 to this Current Report onForm8-K,and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits

(d)List of Exhibits




Amendment, dated June29, 2018, by and between Aralez Pharmaceuticals,Inc., Aralez Pharmaceuticals Canada Inc., Pozen Inc., Deerfield Partners, L.P. and Deerfield Private Design Fund III, L.P.

Aralez Pharmaceuticals Inc. Exhibit
EX-10.1 2 a18-16285_1ex10d1.htm EX-10.1 Exhibit 10.1   June 29,…
To view the full exhibit click here


Aralez Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G. Its development products include YOSPRALA and Bilastine. Fibricor (fenofibric acid) is indicated as a complementary therapy along with diet for the treatment of hypertriglyceridemia, and as a complementary therapy along with diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG) and apolipoprotein B (Apo B). Fibricor is also used to increase high-density lipoprotein (HDL) cholesterol (HDL-C) in patients with hypercholesterolemia or mixed dyslipidemia. Cambia (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug (NSAID).

An ad to help with our costs